<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-94 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-94</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-94</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <p><strong>Paper ID:</strong> paper-ed3a84a85060d7df8725f6c030ba05536c952503</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/ed3a84a85060d7df8725f6c030ba05536c952503" target="_blank">Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Immunology</p>
                <p><strong>Paper TL;DR:</strong> This study investigated local (tumor) and peripheral (blood) cellular immunome of patients with melanoma, breast cancer, and brain cancer using a rapid and reliable standardized, multiparameter flow cytometry assay, and provides insight into the innate and adaptive immune cell profile in blood and tumor.</p>
                <p><strong>Paper Abstract:</strong> Immunotherapies are rapidly being integrated into standard of care (SOC) therapy in conjunction with surgery, chemotherapy, and radiotherapy for many cancers and a large number of clinical studies continue to explore immunotherapy alone and as part of combination therapies in patients with cancer. It is evident that clinical effectiveness of immunotherapy is limited to a subset of patients and improving immunotherapy related outcomes remains a major scientific and clinical effort. Understanding the immune cell subset phenotype and activation/functional status (cellular immunome) prior to and post therapy is therefore critical to develop biomarkers that (1) will predict if a patient will respond to immunotherapy and (2) are a result of immunotherapy. In this study, we investigated local (tumor) and peripheral (blood) cellular immunome of patients with melanoma, breast cancer, and brain cancer using a rapid and reliable standardized, multiparameter flow cytometry assay. We used this approach to monitor changes in the peripheral cellular immunome in women with breast cancer undergoing SOC therapy. Our analysis is unique because it is conducted using matched fresh tumor tissue and blood from patients in real-time, within 2â€“3 h of sample acquisition, and provides insight into the innate and adaptive immune cell profile in blood and tumor. Specific to blood, this approach involves no manipulation and evaluates all immune subsets such as T cells, B cells, natural killer (NK) cells, monocytes, dendritic cells (DCs), neutrophils, eosinophils, and basophils using 0.5 ml of blood. Analysis of the corresponding tumor provides much needed insight into the phenotype and activation status of immune cells, especially T and B cells, in the tumor microenvironment vs. the periphery. This analysis will be used to assess baseline and therapy-mediated changes in local and peripheral cellular immunome in patients with glioblastoma, breast cancer, and melanoma in planned immunotherapy clinical studies.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e94.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e94.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Oncolytic virus + checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Intratumoral oncolytic virotherapy combined with immune checkpoint blockade (e.g., anti-PD-1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Strategy that uses intratumoral delivery of oncolytic viruses to activate innate immunity, promote local immune cell recruitment and antigen presentation, and thereby enhance or restore responsiveness to systemic immune checkpoint blockade (anti-PD-1/PD-L1) in tumors that are resistant or immune-excluded.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>anti-PD-1 (checkpoint blockade)</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-PD-1 / anti-PD-L1)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>resistance to immune checkpoint blockade (adaptive / acquired or immune-excluded tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Poor intratumoral T cell infiltration / immune exclusion and insufficient innate priming and antigen presentation in the tumor microenvironment leading to lack of pre-existing anti-tumor immunity (impaired T cell recruitment/priming and immunosuppressive TME)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>Oncolytic virotherapy + checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>Intratumoral oncolytic virus (examples cited: talimogene laherparepvec [T-VEC], oncolytic poliovirus PVSRIPO) + systemic anti-PD-1/PD-L1 checkpoint inhibitor</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Oncolytic viruses locally lyse tumor cells and activate innate immune cells, increasing antigen release and presentation and recruiting/activating T cells in the tumor; this can convert 'cold' or immune-excluded tumors into 'hot' tumors and thereby sensitize them to systemic PD-1/PD-L1 blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mentioned evidence includes preclinical models and cited clinical studies (preclinical studies showing increased intratumoral T cell infiltration; clinical experience with oncolytic agents in melanoma and clinical PVSRIPO study in GBM are cited).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Described generally for tumors resistant to checkpoint blockade; melanoma is discussed in the paper as a tumor type where oncolytic virotherapy is relevant (T-VEC in advanced melanoma referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>No specific numerical clinical outcomes for the combination in melanoma are provided in this paper; the paper cites that talimogene laherparepvec improved durable response rate in advanced melanoma (reference cited) and that oncolytic virotherapy can improve responses to anti-PD-1 in cited literature, but this manuscript gives no new numerical efficacy metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td>Paper highlights pre-existing anti-tumor immunity and intratumoral T cell infiltration as important determinants of checkpoint responsiveness and suggests that cellular immunome features (e.g., tumor-infiltrating T cells, PD-1 expression, Treg levels) could serve as predictive biomarkers; no validated predictive biomarker for the combination is reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>Not specified in this paper (described generally as intratumoral oncolytic delivery in combination with systemic checkpoint blockade; sequencing/scheduling details not provided).</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer', 'publication_date_yy_mm': '2019-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e94.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e94.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PVSRIPO + checkpoint blockade (hypothesized)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Recombinant oncolytic poliovirus (PVSRIPO) combined with immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The authors discuss PVSRIPO (an oncolytic poliovirus) as an intratumoral virotherapy that activates innate immune cells and primes adaptive antitumor responses, and they propose combining PVSRIPO with checkpoint blockade as a strategy to understand and potentially overcome resistance to immune checkpoint therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Recurrent glioblastoma treated with recombinant poliovirus.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>immune checkpoint blockade (anti-PD-1/PD-L1 implied)</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-PD-1 / anti-PD-L1)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>resistance to immune checkpoint blockade (context: tumors not responding to checkpoint blockade; implied acquired/adaptive resistance)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Impaired innate activation and insufficient priming of adaptive antitumor immunity leading to failure of checkpoint blockade; PVSRIPO acts by infecting/killing tumor cells and activating innate immune cells to prime CTLs</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>PVSRIPO (oncolytic poliovirus) + checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>PVSRIPO (recombinant oncolytic poliovirus) + systemic immune checkpoint inhibitor (anti-PD-1/PD-L1 agents implied)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>PVSRIPO infects and kills tumor cells while activating innate immune cells and type I IFN-dominant dendritic cell activation, leading to priming of tumor antigen-specific CTLs; this innate/adaptive priming could sensitize tumors to checkpoint blockade and potentially overcome resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>PVSRIPO has clinical data in glioblastoma (clinical study cited); combination with checkpoint blockade is presented as a rationale/hypothesis and not as a tested clinical regimen within this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Discussed in context of patients with recurrent glioblastoma for PVSRIPO clinical data; the combination is proposed as a general strategy that could apply to checkpoint-resistant tumors including melanoma, but no melanoma patients treated with PVSRIPO are reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>The paper cites that PVSRIPO produced durable long-term survival in a subset of recurrent GBM patients (reference cited) but does not provide numerical outcomes for PVSRIPO combined with checkpoint blockade, nor any melanoma-specific clinical outcomes for this combination.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td>The manuscript emphasizes the need to identify immune cellular biomarkers (cellular immunome) to select patients likely to benefit from PVSRIPO and combinations, but does not report validated biomarkers predictive of response to PVSRIPO + checkpoint blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer', 'publication_date_yy_mm': '2019-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. <em>(Rating: 2)</em></li>
                <li>Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. <em>(Rating: 2)</em></li>
                <li>Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. <em>(Rating: 2)</em></li>
                <li>Recurrent glioblastoma treated with recombinant poliovirus. <em>(Rating: 1)</em></li>
                <li>Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>